Jian-Hua Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jian-Hua Zhu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Min Pan
Department of Cardiology, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong 226001, People’s Republic of China
2 shared publicationsChu Chen
Department of Cardiology, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong 226001, People’s Republic of China
1 shared publicationHai-Yan Pan
Department of Cardiology, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong 226001, People’s Republic of China
1 shared publicationHong Luan
Department of Cardiology, Ningxia People’s Hospital, 148 West Huaiyuan Road, Yinchuan 750021, People’s Republic of China
1 shared publicationHong-Mei Li
Department of cardiology, Affiliated Hospital of Nantong University, Nantong, P.R. China
1 shared publicationJin-Guo Zheng
Department of Cardiology, Xinghua People’s Hospital, 247 Fengshou Road, Xinghua 225700, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 1 January 2007
- Published by Japanese Society of Hypertension in Hypertension Research
- Vol. 30 (1) , 31-37
Angiotensin-Converting Enzyme Gene 2350 G/A Polymorphism Is Associated with Left Ventricular Hypertrophy but Not Essential Hypertension
The angiotensin-converting enzyme (ACE) gene (ACE) is one of the most studied candidate genes related to essential hypertension (EH) and left ventricular hypertrophy (LVH). ACE rs4343 synonymous coding polymorphism (2350 G/A) is known among the polymorphisms of this gene to have the most significant effect on plasma ACE concentrations. The aim of the present study was to investigate the association of this polymorphism with EH and LVH in 440 subjects (246 EH patients and 194 controls) from a Chinese Han population. In this study, 2350 G/A genotypes were identified by polymerase chain reaction and restriction digestion in all study participants, and left ventricular mass was assessed by 2-mode echocardiography in 178 untreated EH patients. There was no significant difference in either genotype distribution (p=0.3659) or allele frequency (p=0.1453) between EH and control groups. In addition, the 2350 G/A polymorphism had no effect on blood pressure in either controls or untreated EH patients. The distribution of genotypes differed significantly when patients with LVH were examined, i.e., 14.71% GG, 54.41% GA, and 30.88% AA patients had this complication, and 36.36% GG, 42.73% GA, and 20.91% AA patients did not (p=0.0070). The LVH patients had a higher A allele frequency (58.09%) than patients without LVH (42.27%) (p=0.0037). Logistic regression analysis revealed that the association between the A allele and LVH was independent of age, blood pressure, and body mass index. The relative risk of LVH in patients bearing the A allele (GA+AA group) compared with that of GG hypertensive patients was 3.31 (95% confidence interval [CI]: 1.43 to 7.68). These findings suggest an association between LVH and the 2350A allele in hypertensive patients.
- 1 January 2007
- Published by Japanese Society of Hypertension in Hypertension Research
- Vol. 30 (1) , 31-37
Open AccessAngiotensin-Converting Enzyme Gene 2350 G/A Polymorphism Is Associated with Left Ventricular Hypertrophy but Not Essential Hypertension
The angiotensin-converting enzyme (ACE) gene (ACE) is one of the most studied candidate genes related to essential hypertension (EH) and left ventricular hypertrophy (LVH). ACE rs4343 synonymous coding polymorphism (2350 G/A) is known among the polymorphisms of this gene to have the most significant effect on plasma ACE concentrations. The aim of the present study was to investigate the association of this polymorphism with EH and LVH in 440 subjects (246 EH patients and 194 controls) from a Chinese Han population. In this study, 2350 G/A genotypes were identified by polymerase chain reaction and restriction digestion in all study participants, and left ventricular mass was assessed by 2-mode echocardiography in 178 untreated EH patients. There was no significant difference in either genotype distribution (p=0.3659) or allele frequency (p=0.1453) between EH and control groups. In addition, the 2350 G/A polymorphism had no effect on blood pressure in either controls or untreated EH patients. The distribution of genotypes differed significantly when patients with LVH were examined, i.e., 14.71% GG, 54.41% GA, and 30.88% AA patients had this complication, and 36.36% GG, 42.73% GA, and 20.91% AA patients did not (p=0.0070). The LVH patients had a higher A allele frequency (58.09%) than patients without LVH (42.27%) (p=0.0037). Logistic regression analysis revealed that the association between the A allele and LVH was independent of age, blood pressure, and body mass index. The relative risk of LVH in patients bearing the A allele (GA+AA group) compared with that of GG hypertensive patients was 3.31 (95% confidence interval [CI]: 1.43 to 7.68). These findings suggest an association between LVH and the 2350A allele in hypertensive patients.